# EDGAR Filing Document

**Accession Number:** 0001990829
**File Stem:** 0001493152-25-028760
**Filing Date:** 2025-12
**Character Count:** 13119
**Document Hash:** 4b56eca228158b662a19c91b10d51108
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-028760.hdr.sgml**: 20251222

**ACCESSION NUMBER**: 0001493152-25-028760

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251222

**DATE AS OF CHANGE**: 20251222

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CDT Equity Inc.
- **CENTRAL INDEX KEY:** 0001896212
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 873272543
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93313
- **FILM NUMBER:** 251592447

**BUSINESS ADDRESS:**
- **STREET 1:** 4851 TAMIAMI TRAIL NORTH
- **STREET 2:** SUITE 200
- **CITY:** NAPLES
- **STATE:** FL
- **ZIP:** 34103
- **BUSINESS PHONE:** (646) 491 9132

**MAIL ADDRESS:**
- **STREET 1:** 4851 TAMIAMI TRAIL NORTH
- **STREET 2:** SUITE 200
- **CITY:** NAPLES
- **STATE:** FL
- **ZIP:** 34103

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CONDUIT PHARMACEUTICALS INC.
- **DATE OF NAME CHANGE:** 20230922

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Murphy Canyon Acquisition Corp.
- **DATE OF NAME CHANGE:** 20211130
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Corvus Capital Ltd.
- **CENTRAL INDEX KEY:** 0001990829

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** WILLOW HOUSE, CRICKET SQUARE PO BOX 709
- **CITY:** GRAND CAYMAN
- **PROVINCE COUNTRY:** E9
- **ZIP:** KY1 - 1107
- **BUSINESS PHONE:** 44 7766 766766

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** WILLOW HOUSE, CRICKET SQUARE PO BOX 709
- **CITY:** GRAND CAYMAN
- **PROVINCE COUNTRY:** E9
- **ZIP:** KY1 - 1107

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 4)**

**CDT Equity Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.0001 per share**

*(Title of Class of Securities)*

**20678X403**

*(CUSIP Number)*

**Andrew Regan**<br>Corvus Capital Ltd., FL. 2, Willow House<br>Cricket Square PO Box 709<br>Grand Cayman E9 KY1-1107<br>44 7766 766766

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**12/08/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **20678X403** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Corvus Capital Ltd.** | Name of reporting person<br>**Corvus Capital Ltd.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**246667.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**246667.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**246667.00** | Aggregate amount beneficially owned by each reporting person<br>**246667.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[x] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[x] | |
| 13 | Percent of class represented by amount in Row (11)<br>**12.2%** | Percent of class represented by amount in Row (11)<br>**12.2%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **20678X403** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Andrew Regan** | Name of reporting person<br>**Andrew Regan** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X0** | Citizenship or place of organization<br>**X0** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**140005.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**246667.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**140005.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**246667.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**386672.00** | Aggregate amount beneficially owned by each reporting person<br>**386672.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[x] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[x] | |
| 13 | Percent of class represented by amount in Row (11)<br>**19.1%** | Percent of class represented by amount in Row (11)<br>**19.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.0001 per share

**(b) Name of Issuer:**
CDT Equity Inc.

**(c) Address of Issuer's Principal Executive Offices:**
4851 Tamiami Trail North, Suite 200, Naples, FL, 34103

The information contained in "Item 1. Security and Issuer." of the Schedule 13D is not being amended by this Amendment No. 4.

This Amendment No. 4 to Schedule 13D (this "Amendment No. 4") relating to the shares of common stock, par value $0.0001 per share ("Common Stock"), of CDT Equity Inc., a Delaware corporation formerly known as Conduit Pharmaceuticals Inc. (the "Issuer"), amends and supplements the Schedule 13D (the "Original Schedule 13D") originally filed by the reporting persons named therein with the Securities and Exchange Commission (the "Commission") on September 29, 2023, as amended by Amendment No. 1 to the Original Schedule 13D, filed by such reporting persons with the Commission on September 19, 2024 ("Amendment No. 1"), as amended by Amendment No. 2 to the Original Schedule 13D, filed by such reporting persons with the Commission on July 31, 2025 ("Amendment No. 2"), as amended by Amendment No. 3 to the Original Schedule 13D, filed by such reporting persons with the Commission on September 22, 2025 ("Amendment No. 3" and, together with the Original Schedule 13D, the "Schedule 13D").

Except as specifically amended below, all other provisions of the Schedule 13D remain in effect. Capitalized terms used herein but not defined herein have the respective meanings ascribed to them in the Schedule 13D.

**Item 4. Purpose of Transaction**

"Item 4. Purpose of Transaction." of the Schedule 13D is being amended by this Amendment No. 4 to add the following:

See Item 3. Corvus acquired the CDT Shares and Pre-Funded Warrants for investment purposes.

**Item 5. Interest in Securities of the Issuer**

**(a)**
"Item 5. Interest in Securities of the Issuer" of the Schedule 13D is hereby amended and restated by this Amendment No. 4 as follows:

(a)-(b) The percentage ownership of shares of Common Stock set forth in this Amendment No. 4 is based upon 2,019,202 shares of Common Stock outstanding as of December 12, 2025, as verified with the Issuer on December 18, 2025.

Corvus beneficially owns 246,667 shares of Common Stock, including 227,304 shares of Common Stock owned directly by Corvus, 14 shares of Common Stock owned directly by Algo Holdings, Inc., its wholly-owned subsidiary ("Algo"), and 19,349 shares of Common Stock owned directly by Manoira Corporation ("Manoira"), of which Corvus is owner of 99% of its equity interests, which represents approximately 12.2% of the issued and outstanding shares of Common Stock as of December 12, 2025, and excluding 3,685,815 Pre-Funded Warrant Shares. The ability to exercise any or all of the Pre-Funded Warrants is subject to the receipt of Stockholder Approval. In addition, under the terms of the Pre-Funded Warrants, Corvus will not have the right to exercise any portion of the Pre-Funded Warrants if Corvus (together with its affiliates) would beneficially own in excess of 49.99% of the number of the Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants.

Dr. Regan beneficially owns 386,672 shares of Common Stock, including 140,005 shares of Common Stock held directly by Dr. Regan, 227,304 shares of Common Stock owned directly by Corvus, 14 shares of Common Stock owned directly by Algo and 19,349 shares of Common Stock owned directly by Manoira, which represents approximately 19.1% of the issued and outstanding shares of Common Stock as of December 12, 2025. Dr. Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. Dr. Regan is the sole director of Manoira of which Corvus is the 99.0% owner of its equity interests. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus, Algo and Manoira. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

**(b)**
The Reporting Persons have the power to vote or dispose of the shares of Common Stock, or direct the vote or disposition thereof, as follows:

Corvus

Sole power to vote or to direct the vote: 0
Shared power to vote or to direct the vote: 246,667
Sole power to dispose or to direct the disposition of: 0
Shared power to dispose or to direct the disposition of: 246,667

Dr. Regan

Sole power to vote or to direct the vote: 140,005
Shared power to vote or to direct the vote: 246,667
Sole power to dispose or to direct the disposition of: 140,005
Shared power to dispose or to direct the disposition of: 246,667

To the Reporting Persons' knowledge, the other individuals named in Item 2 above do not beneficially own any shares of Common Stock.

(c) Except as set forth in Item 4 of this Amendment No. 4, none of the Reporting Persons, or, to the knowledge of the Reporting Persons, any of the individuals named in Item 2 above, have engaged in any transaction with respect to the shares of Common Stock during the sixty (60) days prior to the trigger date for the filing of this Amendment No. 4.

(d) Other than as described in Item 4 above, no other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities covered by this Amendment No. 4.

(e) Not applicable.

**(c)**
—

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

"Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer" of the Schedule 13D is being amended by this Amendment No. 4 to add the following:

The disclosure in Item 4 hereof with respect to the Agreement and the Pre-Funded Warrant is incorporated herein by reference.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Corvus Capital Ltd.

**Signature:** /s/ Andrew Regan

**Name/Title:** Andrew Regan/Chief Executive Officer

**Date:** 12/22/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Andrew Regan

**Signature:** /s/ Andrew Regan

**Name/Title:** Andrew Regan

**Date:** 12/22/2025